Pharma BD Deal Intelligence
Novartis and Orionis will use Orionis's Allo-Glue platform, together with its AI-driven discovery engine, to accelerate target and ligase profiling and…
Novartis has a track record of returning to its preferred molecular glue partners; the second Orionis deal, worth up to $1.4B, comes as molecular glue tech…
Orionis inks molecular glue collaboration with Novartis — factual trade-press coverage of the multi-year partnership expanding the companies' existing…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Novartis and Orionis Biosciences expanded their relationship into a second multi-year strategic collaboration to discover and develop molecular glue medicines against challenging targets across multiple disease areas, announced June 10, 2026. Orionis receives $40 million upfront and is eligible for research, development and commercial milestones of up to $1.4 billion plus tiered royalties. Novartis leads development and commercialization of resulting candidates; specific targets are undisclosed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Orionis Biosciences, Inc. (this deal) | 2026 | $1.4B | 59 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2026 deals · Novartis AG deals · Multiple (undisclosed) deals